Skip to content

Effect of Intravenous S-Ketamine on Opioid Consumption and Postoperative Pain in Patients Undergoing Thyroidectomy: A Randomized, Controlled Trial

Effect of Intravenous S-Ketamine on Opioid Consumption and Postoperative Pain in Patients Undergoing Thyroidectomy: A Randomized, Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053459
Enrollment
Unknown
Registered
2021-11-21
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroidectomy

Interventions

experimental group:Patients in the ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 µg/kg/min S-ketamine in saline until 30 min prior to the
Placebo group:0.9% normal saline

Sponsors

Department of Anesthesiology and Perioperative Medicine, Second Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Selected patients with thyroid excision; 2. Age is not limited, ASA I-II level; 3. After fully explaining the contents of the clinical trial, voluntarily join and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe pulmonary hypertension, arrhythmia or cardiac insufficiency; 2. Patients with liver and kidney dysfunction; 3. Patients with increased intracranial pressure or intraocular pressure; 4. Patients who have recently taken analgesic and sedative drugs; 5. Patients with chronic pain in the past; 6. Mental disorders or alcohol and drug abusers; 7. Patients who are allergic to the drugs used in the study; 8. Patients who are pregnant or breastfeeding; 9. Patients who refuse to use postoperative analgesia; 10. Patients who have participated in other treatments in the last 6 months (when consent is obtained); 11. Patients who are judged to lack the ability to consent; 12. Others, patients who are judged as inappropriate by the clinically responsible doctor or the clinically-in-charge doctor.

Design outcomes

Primary

MeasureTime frame
Amount of sufentanil during Operation;

Secondary

MeasureTime frame
Amount of analgesic medication after surgery;The amount of propofol during surgery;The amount of remifentanil during surgery;The amount of nonsteroidal anti-inflammatory drugs during surgery;Blood pressure, heart rate, BIS values at various points in the operation;The amount of vascular active drugs during surgery;Postoperative 0.5, 2, 4, 6, 12, 24h rest, movement NRS score;Sleep score at night after surgery;Postoperative time out of bed days in hospital;NRS scores of pain at 3 and 6 months postoperatively;Anesthesia time, surgery time, recovery time;Postoperative 30min RASS sedative score;Postoperative adverse reactions;

Countries

China

Contacts

Public ContactWu Yun

Department of Anesthesiology and Perioperative Medicine, Second Affiliated Hospital of Anhui Medical University

wuyunanyi@163.com+86 13865958254

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026